Oncotarget

Research Papers:

Extracting tumor tissue immune status from expression profiles: correlating renal cancer prognosis with tumor-associated immunome

Omri Teltsh, Angel Porgador and Eitan Rubin _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:33191-33205. https://doi.org/10.18632/oncotarget.5052

Metrics: PDF 1087 views  |   HTML 1279 views  |   ?  


Abstract

Omri Teltsh1, Angel Porgador1,*, Eitan Rubin1,*

1The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, The National Institute for Biotechnology in the Negev, Ben-Gurion University of the Negev, Beer Sheva, Israel

*These authors have contributed equally to this work

Correspondence to:

Eitan Rubin, e-mail: erubin@bgu.ac.il

Angel Porgador, e-mail: angel@bgu.ac.il

Keywords: cancer microenvironment, immunome, precision cancer medicine, RNAseq, TCGA

Received: June 07, 2015     Accepted: August 28, 2015     Published: September 07, 2015

ABSTRACT

Investigating the expression of genes in cancer-associated immune cells (immunome) is imperative for prognosis prediction. However, evaluating the expression of immune-associated genes within cancer biopsy is subject to significant inconsistencies related to the sampling methodology. Here, we present immFocus, a method for extracting immune signals from total RNA sequencing of tumor biopsies, intended for immunity depiction and prognosis evaluation. It is based on reducing the variation which biopsy preparation adds to the apparent expression levels of immune genes. We employed immFocus to normalize gene expression with an immune index using data obtained from renal clear cell carcinoma biopsies. Genes that became less variable due to normalization were found to be preferentially immune-related. Moreover, immune-related genes tended to become more prognostic due to the normalization. These results demonstrate, for the first time, that whole transcriptome sequencing can be used for interrogation of a cancer immunome and for advancing immune-based prognosis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 5052